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hepatitis: a differential diagnosis
for classical autoimmune hepatitis
Autoimmune pancreatitis is characterised by
raised serum levels of IgG4 and IgG4-bearing
plasma cells in the inflammatory tissue.1
Similar pathology can also occur in the larger
bile ducts, resembling sclerosing cholangitis.2
We report a patient with hepatitis and chronic
cholecystitis, raised IgG4 level, and IgG4-
bearing plasma cells in the liver and gall
bladder wall, but no evident pancreatic disease.
In January 2003, a cholecystectomy was
undertaken on a 54 year old woman for chronic
cholecystitis. The extracted gall bladder
showed lymphoplasmacytic infiltration and
subserosal fibrosis. A liver biopsy was done
because of abnormal liver function tests and
showed severe lobular hepatitis with mild
portal inflammation. Plasma cell infiltration
was observed in the portal tracts and parench-
yma, though fibrosis was not significant. IgG4
bearing plasma cell infiltration was found both
in the liver and the gall bladder wall. After six
months, liver function was still abnormal:
aspartate aminotransferase, 234 IU/l (reference
range, 12 to 37); alanine aminotransferase,
487 IU/l (7 to 45); alkaline phosphatase,
478 IU/l (124 to 367); c-glutamyl transpepti-
dase, 581 IU/l (6 to 30); total bilirubin,
46.2 mmol/l (5 to 20); IgG, 2403 mg/dl (870 to
1700). The antinuclear antibody titre (1:80 on
rodent tissue) was abnormal, and tests for
autoantibodies to smooth muscle, double
stranded DNA, and mitochondria were nega-
tive. Infection with hepatitis viruses A, B, and
C, cytomegalovirus, and Epstein-Barr virus was
excluded. HLA DRB1 alleles were *1302 and
*1501.
She denied taking medicines or herbal
remedies.
Ultrasonography, abdominal computed
tomography, endoscopic retrograde cholangio-
graphy, and magnetic resonance cholangio-
pancreatography showed no abnormalities in
the extrahepatic bile ducts or pancreas. A
second liver biopsy, which was done six
months after the first, showed changes asso-
ciated with autoimmune hepatitis, interface
hepatitis, lobular hepatitis, rosette formation,
syncytial multinucleated giant cell change, and
marked plasma cell infiltration (fig 1, panels A to
C). Biliary features, such as cholangitis and
periductal fibrosis, were not evident.
Immunostaining of liver tissue showed abun-
dance of plasma cells with strong immunohis-
tochemical reactivity to IgG4 (fig 1D). The
International Autoimmune Hepatitis Group
(IAIHG) disease score was 18, identifying
definite autoimmune hepatitis3 (table 1).
Treatment was successful with prednisolone 40
mg daily for four weeks, tapered by 5 mg weekly
to 5 mg daily. Serum IgG4 concentrations were
557 mg/dl pretreatment (reference range ,135
mg/dl), 226 mg/dl after one month, and 44 mg/
dl after one year. Serum aspartate aminotrans-
ferase and alanine aminotransferase were 94
and 278 IU/l after one month, 31 and 73 IU/l
after two months, and 22 and 25 IU/l after one
year, respectively.
Raised serum IgG4 concentration and IgG4-
bearing plasma cell infiltrates have a high
sensitivity and specificity for the diagnosis of
autoimmune pancreatitis1 and associated dis-
eases, including sclerosing cholangitis.2 In the
present case, the clinical and histological
criteria for definite autoimmune hepatitis were
met and, additionally, both biopsies showed
hepatitis with abundant IgG4-bearing plasma
cells in the liver and gallbladder.
We previously studied 17 patients with
classic autoimmune hepatitis. Both serum
IgG4 and IgG4-bearing plasma cells were
completely absent in the liver of 13, and a
minor increase in only one index was seen in
four.4 Thus we can identify a new disease
entity—IgG4 associated autoimmune hepati-
tis—which can be differentiated from other
recognised types. Our present case implies that
IgG4 related inflammatory processes can occur
in the hepatic parenchyma in the same way as
in the pancreatobiliary system, and such cases
may resemble autoimmune hepatitis both
clinically and pathologically. As such, detection
of IgG4 and assessment of liver histology using
IgG4 immunostaining may be useful for
differentiating IgG4 related diseases from
definite autoimmune hepatitis. Further studies
are needed on this possible new disease entity
and its impact on the diagnostic guidelines for
autoimmune hepatitis.
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Figure 1 Pathological findings of the second liver biopsy. (A) Portal tracts are enlarged with severe
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observed (H&E,6400). (D) Immunostaining for IgG4 reveals abundant IgG4 bearing plasma cells in a
portal tract (IgG4 immunostaining,6400).
Table 1 Autoimmune hepatitis
score using IAIHG scoring system
Variable/feature Score
Female sex: female +2
ALP:AST ratio: 0.2 (,1.5) +2




AMA positive: negative 0
Hepatitis viral markers: negative +3
Drug history: negative +1








Rosetting of liver cells +1
Total +18
ALP, alkaline phosphatase; AMA, anti-
mitochondrial antibodies; ANA, antinuclear
antibody; AST, aspartate aminotransferase;
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The morphine–prostigmine
provocation (Nardi) test for
sphincter of Oddi dysfunction:
results in healthy volunteers and in
patients before and after
transduodenal sphincteroplasty
and transampullary septectomy
Sphincter of Oddi dysfunction is a complex and
poorly understood syndrome that usually
manifests as pain of apparently biliary or
pancreatic origin in the absence of an organic
cause after conventional investigations.
Transduodenal sphincteroplasty with transam-
pullary septectomy (TDS/TAS) is a therapeutic
option.1 Although biliary manometry is the
gold standard diagnostic test, the morphine–
prostigmine provocation (Nardi) test is
sometimes used to screen patients. A fourfold
increase in either serum amylase or lipase and
reproduction of pain after intramuscular injec-
tion of 10 mg morphine (to induce sphincteric
spasm) and 1 mg prostigmine (to stimulate
pancreatic exocrine secretions) is considered a
positive test.2 3 However, the enzymatic
changes may also occur in healthy subjects
and in patients with irritable bowel syn-
drome,3 4 bringing the clinical value of the test
into question. Conversely, when the Nardi test
was carried out on 70 patients with chronic
abdominal pain, enzyme elevation was
detected in only 23 patients (33%), 16 (70%)
of whom had ampullary stenosis.5
We undertook these studies to characterise
the response to the Nardi test in 20 healthy
young adult subjects and 24 patients with
sphincter of Oddi dysfunction before and after
TDS/TAS. Our diagnosis of sphincter of Oddi
dysfunction was based on clinical history,
HIDA scanning, cross sectional imaging, endo-
scopic retrograde cholangiopancreatography,
and exclusion of luminal pathology. All
patients had significant debilitating upper
abdominal pain requiring regular strong
analgesia and had a poor quality of life.
Patients were Milwaukee class I or II and had
microscopic stenosis/fibrosis, but biliary mano-
metry was not done routinely. We excluded
from the healthy subject study those with
recurrent abdominal pain, gallstones, or pre-
vious abdominal surgery, and those on regular
medicines or with allergies.
Subjects abstained from alcohol for at least
24 hours. After sampling blood for baseline
concentrations of amylase and lipase, subjects
were given 1 ml of 0.9% saline intramuscularly
as a sham test. Blood was resampled one hour
after this injection. Subjects were then given 10
mg morphine and 1 mg prostigmine intramus-
cularly simultaneously and blood samples were
Figure 1 Scatter plot showing maximum increase in serum amylase (top) and lipase (bottom) over
baseline values one hour after the sham test and after provocation with morphine and prostigmine in
healthy subjects. The baseline value has arbitrarily been defined as 1 and increases are shown as
multiples of the baseline value. The dashed line represents 46baseline. A smaller than fourfold
increase over baseline in both amylase and lipase was seen in only four of the 20 subjects.
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